Mon, Apr 21, 2014, 12:13 PM EDT - U.S. Markets close in 3 hrs 47 mins

Recent

% | $
Quotes you view appear here for quick access.

Myriad Genetics Inc. Message Board

  • aecooter33 aecooter33 Aug 26, 2013 1:59 PM Flag

    GeneDx launches BRCA testing

    Looks like Bio-Reference labs just entered the market with BRCA testing.
    GeneDx Introduces Advanced Genetic Test Panels for Inherited Cancer Including Breast and Colon Cancer

    PR Newswire

    GAITHERSBURG, Md., Aug. 26, 2013
    GAITHERSBURG, Md., Aug. 26, 2013 /PRNewswire/ -- GeneDx, one of the world's foremost genetic testing laboratories and a wholly-owned subsidiary of Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) has announced the launch of a comprehensive suite of genetic tests for inherited cancer, including a 26-gene panel for breast and ovarian cancer that includes BRCA1 and BRCA2 and next generation sequencing based multi-gene panels for colorectal cancer, pancreatic cancer, and endometrial cancer.
    GeneDx, the first commercial laboratory to utilize next generation sequencing technologies in a CLIA-environment, is among only a handful of commercial labs in the U.S. currently offering testing for inherited cancer. The laboratory will begin accepting specimens immediately.
    The test offerings include a rapid turn-around test of the BRCA1 and BRCA2 genes combining sequencing and deletion/duplication analysis; an Ashkenazi Jewish panel for the three common Ashkenazi Jewish founder mutations in BRCA1 and BRCA2; a 26-gene panel for breast and ovarian cancer; an 18-gene panel for pancreatic cancer; an 18-gene panel for colorectal cancer; and an 11-gene panel for endometrial cancer. The test panels, which are marketed as OncoGeneDx, also include a Comprehensive Cancer Panel of 35 genes. All panels include deletion/duplication assessment.
    The OncoGeneDx panels utilize the most current data on all the highly penetrant genes associated with inherited cancer, providing rapid results at typically no greater cost than testing for a single gene. GeneDx's OncoGeneDx panels are the most comprehensive on the market today.
    Sherri Bale, Ph.D., Managing Director of GeneDx stated, "We are excited to be launching this suite of tests, as we can now bring our extensive experience in ge

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MYGN
38.35+0.38(+1.01%)12:12 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.